Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.37 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.36 |
| ▸ | HTR3B | O95264 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.36 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124828 | 0.90 | CHRNA7 (0.40) | CHRNA7EZH2HTR3EHTR3BHTR3A | |
| SCHEMBL7120626 | 0.85 | CHRNA7 (0.40) | CHRNA7EZH2HTR3EHTR3BHTR3A | |
| SCHEMBL7117143 | 0.85 | CHRNA7 (0.39) | CHRNA7EZH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7117999 | 0.83 | CHRNA7 (0.42) | CHRNA7EZH2HTR3EHTR3BHTR3A | |
| SCHEMBL7124070 | 0.83 | L3MBTL1 (0.45) | CHRNA7EZH2SMN1; SMN2 | |
| SCHEMBL7114399 | 0.83 | EZH2 (0.44) | EZH2HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL7125311 | 0.83 | CHRNA7 (0.42) | CHRNA7EZH2HTR3EHTR3BHTR3A | |
| SCHEMBL7117164 | 0.83 | CHRNA7 (0.42) | CHRNA7EZH2HTR3EHTR3BHTR3A | |
| SCHEMBL7127524 | 0.82 | CHRNA7 (0.55) | CHRNA7EZH2HTR3EHTR3BHTR3A | |
| SCHEMBL7125285 | 0.82 | CHRNA7 (0.40) | CHRNA7EZH2HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | claimed |
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069296-A1 | Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease | CYP7B1, UGT2B7, CYP1B1 | CHRNA7 397/4885EZH2 462/4885HTR3E 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.